Literature DB >> 19100339

Curcumin protects against electrobehavioral progression of seizures in the iron-induced experimental model of epileptogenesis.

Amar Jyoti1, Pallavi Sethi, Deepak Sharma.   

Abstract

The purpose of the study was to investigate whether dietary intake of curcumin can inhibit the onset and progression of seizures and their associated pathophysiology in experimental FeCl(3)-induced epileptogenesis. Curcumin was considered for this study because it can cross the blood-brain barrier and bind redox-active metal ions. It is also well known for its antioxidative, anticancer, and anti-inflammatory properties. In the present study, seizures were induced by intracortical injection of FeCl(3) into young rats. Synchronized video/EEG recordings were obtained to diagnose the progression of seizures. Short-term treatment with a curcumin-supplemented diet (1500 pp mw/w) significantly inhibited the onset of grade III and IV seizures in rats with iron-induced epilepsy. The lower dose of curcumin (500 ppm) was not effective in inhibiting grade III seizures, but retarded the onset and progression of generalized seizures. The seizure-suppressing potential of curcumin is explained by the observed biochemical, behavioral, and ultrastructural results. Our results indicate that curcumin significantly prevents generalization of electroclinical seizure activity as well as the pathogenesis associated with iron-induced epileptogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100339     DOI: 10.1016/j.yebeh.2008.11.011

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  21 in total

1.  Dietary therapy to promote neuroprotection in chronic spinal cord injury.

Authors:  Langston T Holly; Donald Blaskiewicz; Aiguo Wu; Cameron Feng; Zhe Ying; Fernando Gomez-Pinilla
Journal:  J Neurosurg Spine       Date:  2012-06-26

2.  The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate.

Authors:  Heba S Aboul Ezz; Yasser A Khadrawy; Neveen A Noor
Journal:  Neurochem Res       Date:  2011-07-13       Impact factor: 3.996

Review 3.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

4.  Herbs and spices: unexpected sources of antiepileptogenic drug treatments?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

5.  Effects of curcumin (Curcuma longa) on learning and spatial memory as well as cell proliferation and neuroblast differentiation in adult and aged mice by upregulating brain-derived neurotrophic factor and CREB signaling.

Authors:  Sung Min Nam; Jung Hoon Choi; Dae Young Yoo; Woosuk Kim; Hyo Young Jung; Jong Whi Kim; Miyoung Yoo; Sanghee Lee; Chul Jung Kim; Yeo Sung Yoon; In Koo Hwang
Journal:  J Med Food       Date:  2014-04-08       Impact factor: 2.786

Review 6.  Curcumin: A Review of Its Effects on Epilepsy.

Authors:  Fatemeh Forouzanfar; Muhammed Majeed; Tannaz Jamialahmadi; Amirhosein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Altered lipid metabolism in post-traumatic epileptic rat model: one proposed pathway.

Authors:  Niraj Kumar Srivastava; Somnath Mukherjee; Rajkumar Sharma; Jharana Das; Rohan Sharma; Vikas Kumar; Neeraj Sinha; Deepak Sharma
Journal:  Mol Biol Rep       Date:  2019-01-31       Impact factor: 2.316

8.  Omega-3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: A double-blinded randomized clinical trial.

Authors:  Hadis Sabour; Abbas Norouzi Javidan; Sahar Latifi; Farzad Shidfar; Ramin Heshmat; Seyed-Hassan Emami Razavi; Mohammad Reza Vafa; Bagher Larijani
Journal:  J Spinal Cord Med       Date:  2014-08-06       Impact factor: 1.985

9.  An overview of curcumin in neurological disorders.

Authors:  S K Kulkarni; A Dhir
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

Review 10.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.